Premium
Isatuximab plus carfilzomib and dexamethasone in patients with relapsed multiple myeloma based on prior lines of treatment and refractory status: IKEMA subgroup analysis
Author(s) -
Dimopoulos Meletios A.,
Moreau Philippe,
Augustson Bradley,
Castro Nelson,
Pika Tomas,
Delimpasi Sosana,
De la Rubia Javier,
Maiolino Angelo,
Reiman Tony,
MartinezLopez Joaquin,
Martin Thomas,
Mikhael Joseph,
Yong Kwee,
Risse MarieLaure,
Asset Gaelle,
Marion Sylvia,
Hajek Roman
Publication year - 2023
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.26602
Subject(s) - carfilzomib , lenalidomide , medicine , pomalidomide , refractory (planetary science) , dexamethasone , oncology , hazard ratio , multiple myeloma , population , daratumumab , bortezomib , confidence interval , astrobiology , physics , environmental health